Right you are slimmy: Provenge's best avg. survival is 4.5 months; GVAX's best avg. survival is 35 months.
Gee, which would you rather take?
Factor in that GVAX is off-the-shelf and less expensive than the autologous Provenge, and you have a scenario in which DNDN is trying to gain approval for a treatment that will be obsolete almost as soon as it hits the market (if it ever does).